MX2023013445A - Compuestos heterociclicos sustituidos. - Google Patents
Compuestos heterociclicos sustituidos.Info
- Publication number
- MX2023013445A MX2023013445A MX2023013445A MX2023013445A MX2023013445A MX 2023013445 A MX2023013445 A MX 2023013445A MX 2023013445 A MX2023013445 A MX 2023013445A MX 2023013445 A MX2023013445 A MX 2023013445A MX 2023013445 A MX2023013445 A MX 2023013445A
- Authority
- MX
- Mexico
- Prior art keywords
- substituted heterocyclic
- heterocyclic compounds
- useful
- compounds
- ifnî
- Prior art date
Links
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188498P | 2021-05-14 | 2021-05-14 | |
| US202263318149P | 2022-03-09 | 2022-03-09 | |
| PCT/US2022/029102 WO2022241171A1 (en) | 2021-05-14 | 2022-05-13 | Substituted heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013445A true MX2023013445A (es) | 2023-12-14 |
Family
ID=81927926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013445A MX2023013445A (es) | 2021-05-14 | 2022-05-13 | Compuestos heterociclicos sustituidos. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11866414B2 (enExample) |
| EP (1) | EP4337655A1 (enExample) |
| JP (1) | JP2024518554A (enExample) |
| KR (1) | KR20240008336A (enExample) |
| AU (1) | AU2022271794A1 (enExample) |
| CA (1) | CA3217332A1 (enExample) |
| CL (1) | CL2023003308A1 (enExample) |
| CO (1) | CO2023015226A2 (enExample) |
| IL (1) | IL308421A (enExample) |
| MX (1) | MX2023013445A (enExample) |
| PE (1) | PE20250262A1 (enExample) |
| TW (1) | TW202311247A (enExample) |
| WO (1) | WO2022241171A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102858043B1 (ko) * | 2018-10-30 | 2025-09-10 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 |
| WO2021226208A2 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| KR102698413B1 (ko) | 2020-05-05 | 2024-08-26 | 뉴베일런트, 아이엔씨. | 헤테로방향족 거대환식 에터 화학치료제 |
| CN122520625A (zh) | 2020-12-22 | 2026-08-07 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Ｔｙｋ２抑制劑及其用途 |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| WO2022212489A1 (en) | 2021-03-31 | 2022-10-06 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| EP4337650A1 (en) * | 2021-05-14 | 2024-03-20 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| PE20250262A1 (es) * | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| KR20240008338A (ko) * | 2021-05-14 | 2024-01-18 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| KR20240007242A (ko) * | 2021-05-14 | 2024-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| CN115724830A (zh) * | 2021-08-31 | 2023-03-03 | 浙江文达医药科技有限公司 | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 |
| TW202320768A (zh) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
| CN117263913A (zh) | 2022-06-20 | 2023-12-22 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物、固体形式、制备方法及其用途 |
| WO2024044486A1 (en) * | 2022-08-22 | 2024-02-29 | Ajax Therapeutics, Inc. | Jak2 inhibitor compounds |
| CN120152968A (zh) * | 2022-11-08 | 2025-06-13 | 百时美施贵宝公司 | 取代的杂环化合物 |
| CN118812511A (zh) * | 2023-04-21 | 2024-10-22 | 浙江文达医药科技有限公司 | 作为tyk2抑制剂的杂环化合物及合成和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220766T1 (hr) * | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| LT3601268T (lt) | 2017-03-30 | 2021-05-25 | Bristol-Myers Squibb Company | 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas |
| PE20250262A1 (es) * | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
-
2022
- 2022-05-13 PE PE2023003027A patent/PE20250262A1/es unknown
- 2022-05-13 US US17/743,557 patent/US11866414B2/en active Active
- 2022-05-13 AU AU2022271794A patent/AU2022271794A1/en active Pending
- 2022-05-13 TW TW111118122A patent/TW202311247A/zh unknown
- 2022-05-13 MX MX2023013445A patent/MX2023013445A/es unknown
- 2022-05-13 IL IL308421A patent/IL308421A/en unknown
- 2022-05-13 CA CA3217332A patent/CA3217332A1/en active Pending
- 2022-05-13 EP EP22727672.2A patent/EP4337655A1/en active Pending
- 2022-05-13 WO PCT/US2022/029102 patent/WO2022241171A1/en not_active Ceased
- 2022-05-13 KR KR1020237042720A patent/KR20240008336A/ko active Pending
- 2022-05-13 JP JP2023570165A patent/JP2024518554A/ja active Pending
-
2023
- 2023-11-07 CL CL2023003308A patent/CL2023003308A1/es unknown
- 2023-11-09 CO CONC2023/0015226A patent/CO2023015226A2/es unknown
- 2023-11-30 US US18/524,426 patent/US20240190829A1/en not_active Abandoned
-
2024
- 2024-12-11 US US18/976,869 patent/US20250163004A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023003308A1 (es) | 2024-04-26 |
| IL308421A (en) | 2024-01-01 |
| US20250163004A1 (en) | 2025-05-22 |
| JP2024518554A (ja) | 2024-05-01 |
| US20240190829A1 (en) | 2024-06-13 |
| EP4337655A1 (en) | 2024-03-20 |
| US20220411384A1 (en) | 2022-12-29 |
| US11866414B2 (en) | 2024-01-09 |
| BR112023023425A2 (pt) | 2024-01-30 |
| PE20250262A1 (es) | 2025-01-29 |
| WO2022241171A1 (en) | 2022-11-17 |
| KR20240008336A (ko) | 2024-01-18 |
| CO2023015226A2 (es) | 2023-11-20 |
| AU2022271794A1 (en) | 2024-01-04 |
| CA3217332A1 (en) | 2022-11-17 |
| TW202311247A (zh) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003308A1 (es) | Compuestos heterocíclicos sustituidos | |
| MX2023013351A (es) | Compuestos heterociclicos sustituidos. | |
| MX2021004562A (es) | Compuestos heterociclicos sustituidos con amida para el tratamiento de condiciones relacionadas con la modulacion de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifn-alfa). | |
| JOP20210097B1 (ar) | مركبات 2-أمينو-n-أريل غير متجانس-نيكوتيناميد كمثبطات nav1.8 | |
| PH12020552206A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| PH12019501212A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| MX2020013899A (es) | Derivados de pirazol como inhibidores de malt1. | |
| EA202192134A1 (ru) | Амидзамещенные гетероциклические соединения | |
| JOP20200086B1 (ar) | مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات لـ pi3k-جاما | |
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| EA202191991A1 (ru) | Новые производные гетеротрициклического соединения и их применение | |
| EA202190464A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов pad4 | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| EA202190011A1 (ru) | ПРОИЗВОДНЫЕ ТИОФЕНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, ВЫЗВАННЫХ IgE | |
| MX2023010303A (es) | Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol. | |
| JOP20250149A1 (ar) | مثبطات malt1 | |
| MX2022002443A (es) | Compuestos inhibidores de perk. | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos | |
| WO2019202346A3 (en) | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | |
| WO2020251871A3 (en) | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |